Zifivax vaccine efficacy against the Delta variant reaches 77.47%.

Consumer Services & Health

Lite

Dwi Hadya Jayani 12/10/2021 13:00 WIB

URL has been copied

Memuat...

The efficacy of the Zifivax COVID-19 vaccine against the Delta variant reached 77.47%. This vaccine also demonstrates high efficacy against other COVID-19 variants.

Efficacy of the Zifivax Vaccine against COVID-19 Variants

A Font Kecil
A Font Sedang
A Font Besar

Access single data

Zifivax vaccine efficacy against the Delta variant reaches 77.47%.

Want to get more access to Data Stories with a more affordable price? Subscribe.

By subscribing, you join us in presenting quality data.

Get:

Premium Data Stories access
Comfortable reading without ads
Download data in XLS, PDF, and image format
Access to data source information

Basic

~~Rp100.000~~

Rp50.000/month

Professional

~~Rp100.000~~

Rp150.000/month

Institutional For organizations

We accept the following payments:

Some payment methods are still in the process of being activated.

Efficacy of the Zifivax Vaccine against COVID-19 Variants

Download

Source

A Small Font
A Medium Font
A Bigger Font

The Indonesian Food and Drug Monitoring Agency (BPOM) has granted Emergency Use Authorization (EUA) for the Zifivax COVID-19 vaccine. This vaccine is produced by Anhui Zhifei Longcom Viopharmaceutical from China.

Based on phase 3 clinical trial results, the Zifivax vaccine demonstrates good efficacy, including against new coronavirus variants. Specifically, its efficacy against the Gamma variant is 100%, Alpha 92.93%, Kappa 90%, and Delta 77.47%.

Zifivax efficacy reaches 81.71% calculated 7 days after completing the vaccination. If calculated 14 days after receiving two doses, the efficacy is 81.4%.

BPOM also states that the side effects of the Zifivax vaccine are tolerable. Frequent local side effects include pain at the injection site. Systemic side effects include headache, fatigue, fever, muscle aches, cough, nausea, and diarrhea.

The phase 3 clinical trial of Zifivax involved 28,500 subjects. Indonesia was one of the clinical trial centers, along with Uzbekistan, Pakistan, Ecuador, and China. Approximately 4,000 Indonesian subjects participated in the trial.

Editor : Dimas Jarot Bayu

"Disclosure: This is an AI-generated translation of the original article. We strive for accuracy, but please note that automated translations may contain errors or slight inconsistencies."